Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
May 22 2024 - 8:02AM
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded
with a mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs,
today announced that Michael Raab, President and CEO, and Justin
Renz, chief financial and operations officer, will participate in a
fireside chat at the 2024 Jefferies Global Healthcare Conference on
Wednesday, June 5, 2024 at 10:00 A.M. Eastern Time in New York
City.
To access the live webcast of the panel
presentation please visit the Events and Presentations page within
the Ardelyx website at
https://ir.ardelyx.com/events-and-presentations. A replay of the
panel presentation will be available on the Ardelyx website for 30
days following the event.
About Ardelyx, Inc.Ardelyx was
founded with a mission to discover, develop and commercialize
innovative, first-in-class medicines that meet significant unmet
medical needs. Ardelyx has two commercial products approved in the
United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor).
Ardelyx has agreements for the development and commercialization of
tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL®
(tenapanor) for hyperphosphatemia in Japan. A New Drug Application
for tenapanor for hyperphosphatemia has been submitted in China
with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in
Canada. For more information, please visit https://ardelyx.com/ and
connect with us on X (formerly known as Twitter), LinkedIn and
Facebook.
Investor and Media Contacts:
Caitlin Lowieclowie@ardelyx.com
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
From May 2024 to Jun 2024
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
From Jun 2023 to Jun 2024